Outlook Therapeutics, Inc. revenue

Outlook Therapeutics, Inc.'s revenue was $1.4m in fiscal 2025, down 82.6% on the year before. Since fiscal 2015 ($5.2m) it has grown at a compound -23.0% a year.

Revenue history

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Outlook Therapeutics, Inc.: revenue history, annual
Fiscal year	2015Sept 2015	2016Sept 2016	2017Sept 2017	2018Sept 2018	2019Sept 2019	2025Sept 2025
Revenue	5,219	2,980	3,812	3,088	8,146	1,414
Growth on the year before	—	−42.9%	+27.9%	−19.0%	+163.8%	−82.6%
Gross profit	—	—	—	—	—	57

US$ thousands unless shown otherwise. Fiscal quarters.

Outlook Therapeutics, Inc.: revenue history, quarterly
Quarter	2018 Q3Jun 2018	2018 Q4Sept 2018	2019 Q1Dec 2018	2019 Q2Mar 2019	2019 Q3Jun 2019	2019 Q4Sept 2019	2025 Q3Jun 2025	2025 Q4Sept 2025
Revenue	772	772	1,068	641	584	5,854	1,505	−92
Growth on the same quarter a year before	—	—	—	—	−24.4%	+658.3%	+41.0%	−114.3%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Outlook Therapeutics, Inc.	$8.1m	163.8%	39.8%
Aclaris Therapeutics, Inc.	$8.2m	-51.0%	-35.9%
Coya Therapeutics, Inc.	$8.0m	1793.8%	—
Apollomics Inc.	$8.5m	—	—
Adagene Inc.	$7.7m	7332.8%	—
Roivant Sciences Ltd.	$7.5m	-67.6%	-46.4%

Compare with peers

Head to head: ACRS vs OTLK COYA vs OTLK APLM vs OTLK

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Outlook Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Outlook Therapeutics, Inc.